Treatment and prophylaxis of Pneumocystis carinii pneumonia

M. Castro

Research output: Contribution to journalReview article

40 Scopus citations

Abstract

Early effective management of Pneumocystis carinii pneumonia improves outcome in patients with this disorder. Trimethoprim-sulfamethoxazole remains the agent of choice for treatment of severe P carinii pneumonia. Pentamidine, trimethoprim-dapsone, atovaquone, and other regimens are useful in selected clinical situations. Adjunctive corticosteroids are indicated in patients with acquired immune deficiency syndrome and P carinii pneumonia who have moderate to severe P carinii pneumonia defined as a room air arterial PaO2 less than 70 mm Hg or an alveolar-arterial oxygen gradient of greater than 35 mm Hg. The use of trimethoprim-sulfamethoxazole, dapsone, and aerosolized pentamidine in immunocompromised patients without AIDS is also reviewed.

Original languageEnglish
Pages (from-to)296-303
Number of pages8
JournalSeminars in Respiratory Infections
Volume13
Issue number4
StatePublished - Dec 21 1998

Fingerprint Dive into the research topics of 'Treatment and prophylaxis of Pneumocystis carinii pneumonia'. Together they form a unique fingerprint.

  • Cite this